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Effectiveness of Subcutaneously
Administered Leuprolide Acetate
to Achieve Low Nadir Testosterone
in Prostate Cancer Patients
Christopher M. Pieczonka, MD,1 Przemyslaw Twardowski, MD,2 Joseph Renzulli II, MD,3
Jason Hafron, MD,4 Deborah M. Boldt-Houle, PhD,5 Stuart Atkinson, MB ChB,5 Scott Eggener, MD6
1Associated Medical Professionals, Syracuse, NY; 2Providence Hospital Santa Monica, Santa Monica, CA;
3Brown University, Providence, RI; 4Michigan Institute of Urology, Troy, MI; 5Tolmar Pharmaceuticals Inc.,
Lincolnshire, IL; 6University of Chicago, Chicago, IL

Evidence suggests lower nadir testosterone levels during the first year of androgen
deprivation therapy improve advanced prostate cancer clinical outcomes. We evaluated
pivotal trials for subcutaneously administered leuprolide acetate (1-, 3-, 4-, and 6-month
doses) to determine nadir testosterone levels. Pooled analysis showed 99%, 97%, and
91% of patients reached nadir testosterone #20, #10, and #5 ng/dL respectively
(median #3 ng/dL). Across all available categories, $88% of patients reached nadir
testosterone #5 ng/dL, and ,3% experienced a microsurge. Achievement and maintenance of low nadir testosterone levels may improve progression-free survival and time
to onset of castrate-resistant prostate cancer.
[Rev Urol. 2018;20(2):63–68 doi: 10.3909/riu0798]

®

© 2018 MedReviews , LLC

KEY WORDS
Prostate cancer • Leuprolide acetate • Nadir testosterone • Androgen deprivation therapy •
LHRH agonist

P

rostate cancer (PCa) is the second most common cancer afflicting men in the United States,
with approximately 13% of men receiving this
diagnosis during their lifetime.1 PCa is an androgendependent neoplasm and proliferates in the presence
of testosterone (T).2 Suppression of T can inhibit the

growth of cancer and is the underlying concept for
androgen deprivation therapy (ADT) based on the
original research conducted by Huggins and Hodges
in 1941.3 Luteinizing hormone-releasing hormone
(LHRH) agonists such as leuprolide acetate (LA) are
the most commonly used drugs for ADT with the
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Low Nadir Testosterone With Leuprolide Acetate for Prostate Cancer continued
Fort Collins, CO). The LA formulations are composed of a unique,
biodegradable, dual polymerbased, extended-release delivery
system. SC-LA is available in 1-, 3-,
4-, and 6-month doses that form
solid implants upon interaction
with SC fluid and subsequently
slowly release LA.14,15 SC-LA
maintains mean serum LA levels
between 0.1 and 1.0 ng/mL and
produces consistent T suppression
to #20 ng/dL.16,17

Materials and Methods

Study Design
Data were pooled from four prospective, open-label, fixed-dose
clinical trials in patients with
advanced PCa.14-17 Briefly, patients
aged 40 to 86 years with PCa and
no prior use of ADT received one
of four formulations of SC-LA: (1)
7.5 mg every 28 days for 24 weeks
(1-month formulation; n 5 120);
(2) 22.5 mg every 84 days for 24
weeks (3-month formulation; n 5
117); (3) 30 mg every 112 days for
32 weeks (4-month formulation;
n 5 90); and (4) 45 mg every 168
days for 48 weeks (6-month formulation; n 5 111) in accordance
with the manufacturer’s instructions. The primary endpoint was
serum T and secondary endpoints

included serum LH, bone pain, urinary symptoms, and World Health
Organization (WHO) performance
status. Serum T concentrations
were measured at screening, baseline, 2, 4, and 8 hours after dosing,
days 1, 2, 3, and 7, and then every
week until the next dose, following which the sampling schedule
was repeated until the end of each
study.
Assessments
Serum T was measured by radioimmunoassay with an LOQ of
3 ng/dL; values below this level were
recorded as #3 ng/dL. Nadir T was
defined as the lowest value observed
during treatment. Serum T and
nadir T concentrations were summarized using descriptive statistics. Microsurges were identified as
absolute increases in T of .25 ng/dL
within 4 weeks after administration of a second dose. The onset of
T suppression and the proportion
of time serum T remained below
50 ng/dL, 20 ng/dL, and 10 ng/dL
levels were calculated by extrapolating the point at which the T level
first crossed the target, calculating
the total time T levels remained
below the target, and then dividing
this by the total time after the target
was first achieved (Figure 1).

50
Serum Testosterone (ng/dL)

objective of reducing T to castrate
levels.
In the United States, the biochemical and regulatory definition
of castration is T ,50 ng/dL, based
on the sensitivity of the assays
available when ADT was first
developed 50 years ago.2,4 With the
advent of improved assays, T now
can be measured to much lower
limits of quantification (LOQ)
of ,3 ng/dL.5 T levels of 20 to
32 ng/dL during ADT are associated with a delay in onset of castrate-resistant PCa (CRPC) and
lower risk of death for patients
compared with those with higher T
levels,2,6 suggesting the lowest possible serum T should be the objective of ADT. Consequently, in the
2012 Bethesda consensus published
by a group of US experts, a 20 ng/dL
threshold for serum T during ADT
in patients with advanced PCa was
recommended, although American
Urological Association (AUA) and
National Comprehensive Cancer
Network (NCCN) guidelines have
not adopted this recommendation.7
In 2014, the European Association
of Urology (EAU) updated its
guidelines for the treatment of PCa
to redefine target level of T during
ADT to ,20 ng/dL.8
Nadir serum T, the lowest value
during ADT, has been associated
with delay in disease progression and improved survival.9,10
However, although data on nadir
T levels have been reported with
some therapies (ie, abiraterone
acetate with ADT),11-13 no data
have been published on nadir T
levels achieved with LHRH agonist
monotherapy.
To address this gap in knowledge, a secondary evaluation was
conducted by pooling patients
from four pivotal trials of LA
injected subcutaneously (SC)
(SC-LA; ELIGARD®, leuprolide
acetate for injectable suspension;
Tolmar Pharmaceuticals, Inc.,
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Figure 1. Proportion of time testosterone below suppression target* (illustrative for T #20 ng/dL).
*Proportion of time below target calculated by dividing the total time below target by the time after target
first achieved.
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Patient Demographics and
Baseline Characteristics
There were 120, 117, 90, and 111
patients in the 1-, 3-, 4-, and 6-month
trials, respectively. Baseline characteristics and demographics were
similar between study cohorts and
mean baseline serum T concentrations ranged from 361 to 386 ng/dL
(Table 1).

respectively (Figure 2A). These
durations were the same in each
trial, except for the 1-month formulation where the median onset
of T #10 ng/dL was 7 days earlier
at 28 days. The mean proportions
of time T suppression was maintained below each target were 100%
for T #50 ng/dL, 94% to 99% for
T #20 ng/dL, and 66% to 85% for
T #10 ng/dL (Figure 2B).

Onset and Maintenance of
Testosterone Suppression
In the pooled population, median
onsets of T #50, #20, and
#10 ng/dL were 21, 28, and 35 days,

Nadir Testosterone
Pooled analysis showed 99%, 97%,
and 91% of patients reached nadir
T #20 ng/dL, #10 ng/dL, and
#5 ng/dL, respectively, with 80%

Results

achieving a nadir T below the
LOQ of 3 ng/dL (Figure 3). When
comparing each formulation, 93%,
88%, 90%, and 93% of patients who
received the 1-, 3-, 4-, and 6-month
doses, respectively, reached a nadir
T #5 ng/dL.
Testosterone Microsurges
Microsurge in T occurred in
0.9% to 3.4% (pooled 1.9%) of
patients across the four studies
after the second dose (Table 2).
Of the eight patients who experienced microsurge, six maintained
T below 50 ng/dL and two patients
exceeded it.

TABLE 1
Patient Demographics and Baseline Characteristics
SC-LA Formulated With a Biodegradable, Dual Polymer-based,
Extended-release Delivery System Dose Groups
1 Month, 7.5 mg
(n5120)

3 Month, 22.5 mg
(n5117)

4 Month, 30 mg
(n590)

6 Month, 45 mg
(n5111)

72.8 (52-85)

73.1 (46-85)

73.5 (53-84)

73.2 (50-86)

40-49

0

1 (0.9)

0

0

50-59

8 (6.7)

6 (5.1)

6 (6.7)

6 (5.4)

60-69

28 (23.3)

27 (23.1)

20 (22.2)

25 (22.5)

70-79

60 (50.0)

52 (44.4)

42 (46.7)

55 (49.6)

80-89

24 (20.0)

31 (26.5)

22 (24.4)

25 (22.5)

Height, in, mean (range)

69.0 (62-75)

68.2 (55-74)

69.0 (60-78)

68.9 (62-76)

Weight, lbs, mean (range)

185.3 (126-287)

186.1 (130-296)

196.5 (133-313)

190.1 (109-321)

White

92 (76.7)

93 (79.5)

71 (78.9)

84 (75.7)

Black

15 (12.5)

13 (11.1)

10 (11.1)

19 (17.1)

Hispanic

13 (10.8)

7 (6.0)

8 (8.9)

6 (5.4)

Asian

0

3 (2.6)

0

1 (0.9)

Other

0

1 (0.9)

1 (1.1)

1 (0.9)

Mean age (range)
Age, years, n (%)

Race, n (%)

SC-LA, subcutaneously administered leuprolide acetate.
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Figure 2. (A) Median time to testosterone #10, #20, or #50 ng/dL. (B) Proportion of time testosterone levels
maintained #10, #20, or #50 ng/dL.

Safety
The safety profiles in the pivotal trials have been previously described
and, as expected, were consistent
with known effects of LHRH agonist therapy.14–17

Discussion

Treatment of advanced PCa
patients with SC-LA resulted
in reliable T suppression to
#50 ng/dL by 3 weeks, #20 ng/dL

by 4 weeks, and #10 ng/dL by
5 weeks. Nadir T levels were below
the LOQ of 3 ng/dL in 80% and
#5 ng/dL in 91% of the pooled
patient population. SC-LA maintained consistently low T levels,
with 100%, 94% to 99%, and 66%
to 85% of the treatment durations having T levels below 50, 20,
and 10 ng/dL, respectively, across
the four formulations. The incidence of microsurge was 1.9%,
which is lower than reported for

intramuscular-LA (4%) in a phase
3 study.18,19 SC-LA produced profound T suppression to levels
below historic targets and those
achieved by surgical castration.
This T suppression profile may
extend time to disease progression and improve patient survival.9 In some patients, SC-LA
suppresses T to the very low levels
reported with the new androgen
pathway inhibitor drugs for treatment of advanced PCa, such as
abiraterone acetate (alone or combined with ADT).20,21 Abiraterone
(a CYP17A1 inhibitor) with ADT
suppresses T levels to near zero.22
Enzalutamide and apalutamide,
also with ADT, impact the androgen signaling pathway by blocking
the activity of androgens at the AR
within the cells.23 With the recent
approvals of abiraterone in metastatic castrate-sensitive PCa and
apalutamide in non-metastatic
CRPC, androgen pathway inhibitors now have indications across a
wider spectrum of disease, drive
overall T signaling to near zero,
and improve survival and other
endpoints.11,12,22,23 The publications of studies for these drugs
do not disclose the magnitude of
T reductions achieved in patients
who were randomized to the control arms that received ADT alone.
These data would be informative
and might identify differences in
T suppression between various
forms of ADT and their impact on
clinical endpoints.
Achieving very low nadir T levels
during the first year of ADT may
be prognostic for improved cancerspecific survival.9 It would be informative to understand how effective
ADT drugs are in achieving these
very low levels by consistently measuring T throughout treatment.
The results of our analyses confirm
the efficacy of SC-LA in achieving
and maintaining T levels below
20 ng/dL, and reaching nadir T
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Figure 3. Proportion of patients by nadir testosterone level achieved over study duration (n 5 437).

#3 ng/dL in 80% of patients, providing confidence that patients
receiving SC-LA can achieve and
maintain very low T levels.
Potential limitations of these
analyses are the assessment of
nadir T was not a primary objective of the studies and there may
be analytical issues associated with
pooling of data from multiple studies. However, these are mitigated
as the studies had almost identical
designs and objectives, including

consistent assessment of T levels
and use of a single, central laboratory for the assays.
In conclusion, SC-LA provides
consistent, stable, and durable T
suppression to levels far below
those previously defined as adequate for medical castration in
PCa patients. With the increasing
understanding of the relevance of
nadir T levels during ADT, greater
consideration should be given to
the drug and formulation selected

for initiating ADT based on the
available data on T suppression.
Future studies should assess if
there are clinical benefits of
achieving very low nadir T levels
and compare T suppression levels
between various drugs and formulations.
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